Stock Options and Awards	12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock Options and Awards	Note 11 – Stock Options and Awards On May 29, 2015, the Company’s shareholders approved the Ocean Bio-Chem, Inc. 2015 Equity Compensation Plan (the “Plan”). The Plan provides for grants of several types of awards at the discretion of the Equity Grant Committee of the Company’s Board of Directors, including stock options, stock units, stock awards, stock appreciation rights and other stock-based awards. The Plan authorizes the issuance of 630,000 shares of Company common stock, subject to anti-dilution adjustments upon the occurrence of certain events affecting the common stock. During 2021 and 2020, the Company granted stock awards under the Plan aggregating 36,600 and 25,150 shares of common stock, respectively, to officers, key employees, and directors. Following the withholding of an aggregate of 3,500 and 1,456 shares of common stock, respectively, in connection with a tax withholding feature of the Plan, 26,700 and 23,694 shares were issued to the award recipients, during 2021 and 2020, respectively. The shares were fully expensed in the period in which they were awarded. Except for 6,400 shares awarded in 2021 that vested on January 1, 2022, the shares vested immediately upon issuance. Compensation expense related to the stock awards was $407,860 and $312,610 in 2021 and 2020, respectively. The value of the shares the Company withheld for taxes related to the stock awards was $37,800 and $19,991 in 2021 and 2020, respectively. At December 31, 2021, 117,250 shares remained available for future issuance under the Plan. As a result of the adoption of the Plan, no further stock awards will be made under the Company’s equity compensation plans previously approved by its shareholders (the “Prior Plans”). Prior to the May 29, 2015 effective date of the Plan, stock options were granted under the Prior Plans. The Company had no outstanding options under the Prior Plans at December 31, 2021 and 2020. The last tranche of non-qualified options was exercised before their expiration date of April 25, 2020. There was no compensation expense attributable to stock options recognized during 2021 and 2020, and at December 31, 2021 and 2020, there was no unrecognized compensation cost related to share based compensation arrangements During 2020, stock options to purchase an aggregate of 20,000 shares of common stock were exercised. The Company received a total of $20,700, withheld 4,704 shares in connection with the net exercise feature of the stock options and issued an aggregate of 15,296 shares to the option holders who exercised their options.

Stock Options and Awards

12 Months Ended

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

Note 11 – Stock Options and Awards

On May 29, 2015, the Company’s shareholders approved the Ocean Bio-Chem, Inc. 2015 Equity Compensation Plan (the “Plan”). The Plan provides for grants of several types of awards at the discretion of the Equity Grant Committee of the Company’s Board of Directors, including stock options, stock units, stock awards, stock appreciation rights and other stock-based awards. The Plan authorizes the issuance of 630,000 shares of Company common stock, subject to anti-dilution adjustments upon the occurrence of certain events affecting the common stock. During 2021 and 2020, the Company granted stock awards under the Plan aggregating 36,600 and 25,150 shares of common stock, respectively, to officers, key employees, and directors. Following the withholding of an aggregate of 3,500 and 1,456 shares of common stock, respectively, in connection with a tax withholding feature of the Plan, 26,700 and 23,694 shares were issued to the award recipients, during 2021 and 2020, respectively. The shares were fully expensed in the period in which they were awarded. Except for 6,400 shares awarded in 2021 that vested on January 1, 2022, the shares vested immediately upon issuance. Compensation expense related to the stock awards was $407,860 and $312,610 in 2021 and 2020, respectively. The value of the shares the Company withheld for taxes related to the stock awards was $37,800 and $19,991 in 2021 and 2020, respectively. At December 31, 2021, 117,250 shares remained available for future issuance under the Plan. As a result of the adoption of the Plan, no further stock awards will be made under the Company’s equity compensation plans previously approved by its shareholders (the “Prior Plans”).

Prior to the May 29, 2015 effective date of the Plan, stock options were granted under the Prior Plans. The Company had no outstanding options under the Prior Plans at December 31, 2021 and 2020. The last tranche of non-qualified options was exercised before their expiration date of April 25, 2020. There was no compensation expense attributable to stock options recognized during 2021 and 2020, and at December 31, 2021 and 2020, there was no unrecognized compensation cost related to share based compensation arrangements

During 2020, stock options to purchase an aggregate of 20,000 shares of common stock were exercised. The Company received a total of $20,700, withheld 4,704 shares in connection with the net exercise feature of the stock options and issued an aggregate of 15,296 shares to the option holders who exercised their options.